{"nctId":"NCT01452789","briefTitle":"Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome","startDateStruct":{"date":"2011-11"},"conditions":["Neonatal Abstinence Syndrome"],"count":63,"armGroups":[{"label":"sublingual buprenorphine","type":"EXPERIMENTAL","interventionNames":["Drug: sublingual buprenorphine"]},{"label":"oral morphine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oral morphine"]}],"interventions":[{"name":"sublingual buprenorphine","otherNames":["Buprenex"]},{"name":"oral morphine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* â‰¥ 37 weeks gestation\n* Exposure to opiates in utero\n* Demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment\n\nExclusion Criteria:\n\n* Major congenital malformations and/or intrauterine growth retardation\n* Medical illness requiring intensification of medical therapy. This includes, but is not limited to suspected sepsis requiring antibiotic therapy.\n* Hypoglycemia requiring treatment with intravenous dextrose.\n* Bilirubin \\>20 mg/dL (The need for phototherapy is not exclusionary)\n* Concomitant benzodiazepine or severe alcohol abuse , self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother 30 days prior to birth,\n* Concomitant use of Cytrochrom (CYP) 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment\n* Seizure activity or other neurologic abnormality\n* Breast feeding\n* Inability of mother to give informed consent due to co-morbid psychiatric diagnosis","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Length of Treatment","description":"This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Hospitalization","description":"This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Requiring Supplemental Phenobarbital Treatment.","description":"This endpoint will compare requirement number of patients who require use of supplemental phenobarbital.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","description":"Adverse events will be collected, graded by severity, and assessed for causality referent to study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":33},"commonTop":["diaper rash","Rash","Gastrointestinal","Respiratory Infection","anemia"]}}}